BTTX Stock Financials: Financial Performance and Reports

Period	FY-2022	FY-2021	FY-2020	FY-2019
Period Ended	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Operating Revenue	$0.00	$0.00	$8,000.00	$18,000.00
Cost of Revenue	$2.73 M	$1.62 M	$682,000.00	$898,000.00
Gross Profit	-$2.73 M	-$1.62 M	-$674,000.00	-$880,000.00
Gross Profit Ratio	0	0	-84.25	-48.89
Research and Development Expenses	$16.44 M	$19.44 M	$2.98 M	$2.29 M
General & Administrative Expenses	$14.84 M	$8.79 M	$2.46 M	$2.20 M
Selling & Marketing Expenses	$6.98 M	$2.34 M	$216,000.00	$406,000.00
Selling, General & Administrative Expenses	$21.82 M	$11.12 M	$2.67 M	$2.60 M
Other Expenses	$0.00	$0.00	$0.00	$0.00
Operating Expenses	$38.26 M	$30.56 M	$5.65 M	$4.89 M
Cost And Expenses	$38.26 M	$30.56 M	$6.33 M	$5.79 M
Interest Income	$1,491.00	$185.00	$100.00	$11.00
Interest Expense	$1.49 M	$185,000.00	$100,000.00	$11,000.00
Depreciation & Amortization	$2.73 M	$1.62 M	$75,000.00	$72,000.00
EBITDA	-$38.26 M	-$30.56 M	-$6.25 M	-$5.70 M
EBITDA Ratio	0	0	-781	-316.72
Operating Income	-$38.26 M	-$30.56 M	-$6.32 M	-$5.77 M
Operating Income Ratio	0	0	-790.38	-320.72
Total Other Income/Expenses Net	-$1.49 M	-$9.93 M	$89,000.00	-$11,000.00
Income Before Tax	-$39.75 M	-$40.49 M	-$6.23 M	-$5.78 M
Income Before Tax Ratio	0	0	-779.25	-321.33
Income Tax Expense	$7,000.00	-$153,000.00	$153,000.00	$11,000.00
Net Income	-$39.76 M	-$40.34 M	-$6.39 M	-$5.80 M
Net Income Ratio	0	0	-798.38	-321.94
EPS	-1.69	-1.71	-0.85	-0.25
EPS Diluted	-1.69	-1.71	-0.85	-0.25
Weighted Average Shares Out	$23.56 M	$23.60 M	$7.56 M	$23.60 M
Weighted Average Shares Out Diluted	$23.56 M	$23.60 M	$7.56 M	$23.60 M
Link

Better Therapeutics, Inc. (BTTX) Financials